{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T12:11:04Z","timestamp":1764331864861},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2010,10,23]],"date-time":"2010-10-23T00:00:00Z","timestamp":1287792000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1007\/s12185-010-0707-5","type":"journal-article","created":{"date-parts":[[2010,10,22]],"date-time":"2010-10-22T03:16:01Z","timestamp":1287717361000},"page":"563-570","source":"Crossref","is-referenced-by-count":21,"title":["Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma"],"prefix":"10.1007","volume":"92","author":[{"given":"Kensei","family":"Tobinai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michinori","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dai","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naokuni","family":"Uike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilseung","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Ishizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuniaki","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Ando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Taniwaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,10,23]]},"reference":[{"key":"707_CR1","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","volume":"124","author":"S Wullschleger","year":"2006","unstructured":"Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124:471\u201384.","journal-title":"Cell"},{"key":"707_CR2","doi-asserted-by":"crossref","first-page":"7215","DOI":"10.1158\/1078-0432.CCR-06-2254","volume":"12","author":"PH Patel","year":"2006","unstructured":"Patel PH, Chadalavada RS, Chaganti RS, Motzer RJ. Targeting von Hippel-Lindau pathway in renal cell carcinoma. Clin Cancer Res. 2006;12:7215\u201320.","journal-title":"Clin Cancer Res"},{"key":"707_CR3","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1101\/gad.1212704","volume":"18","author":"N Hay","year":"2006","unstructured":"Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2006;18:1926\u201345.","journal-title":"Genes Dev"},{"key":"707_CR4","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1182\/blood-2006-04-016907","volume":"108","author":"S Uddin","year":"2006","unstructured":"Uddin S, Hussain AR, Siraj AK, et al. Role of phosphatidylinositol 3\u2032-kinase\/AKT pathway in diffuse large B-cell lymphoma survival. Blood. 2006;108:4178\u201386.","journal-title":"Blood"},{"key":"707_CR5","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1182\/blood-2006-05-026203","volume":"108","author":"L Leseux","year":"2006","unstructured":"Leseux L, Hamdi SM, Saati T, et al. Syk-dependent mTOR activation in follicular lymphoma cells. Blood. 2006;108:4156\u201362.","journal-title":"Blood"},{"key":"707_CR6","doi-asserted-by":"crossref","first-page":"6589","DOI":"10.1158\/0008-5472.CAN-05-3018","volume":"66","author":"F Vega","year":"2006","unstructured":"Vega F, Medeiros J, Leventaki V, et al. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase\u2013positive anaplastic large cell lymphoma. Cancer Res. 2006;66:6589\u201397.","journal-title":"Cancer Res"},{"key":"707_CR7","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1046\/j.1365-2141.2003.04761.x","volume":"124","author":"F Bertoni","year":"2004","unstructured":"Bertoni F, Zucca E, Cotter FE. Molecular basis of mantle cell lymphoma. Br J Haematol. 2004;124:130\u201340.","journal-title":"Br J Haematol"},{"key":"707_CR8","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ctrv.2006.10.004","volume":"33","author":"LJ Costa","year":"2007","unstructured":"Costa LJ. Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin\u2019s lymphoma. Cancer Treat Rev. 2007;33:78\u201384.","journal-title":"Cancer Treat Rev"},{"key":"707_CR9","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/annonc\/mdn666","volume":"20","author":"J Ruan","year":"2009","unstructured":"Ruan J, Hajjar K, Rafii S, et al. Angiogenesis and antiangiogenic therapy in non-Hodgkin\u2019s lymphoma. Ann Oncol. 2009;20:413\u201324.","journal-title":"Ann Oncol"},{"key":"707_CR10","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1046\/j.1365-2141.1999.01547.x","volume":"106","author":"F Bertolini","year":"1999","unstructured":"Bertolini F, Paolucci M, Peccatori F, et al. Angiogenic growth factors and endostatin in non-Hodgkin\u2019s lymphoma. Br J Haematol. 1999;106:504\u20139.","journal-title":"Br J Haematol"},{"key":"707_CR11","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrd2062","volume":"5","author":"S Faivre","year":"2006","unstructured":"Faivre S, Kroemer G, Raymond E, et al. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov. 2006;5:671\u201388.","journal-title":"Nat Rev Drug Discov"},{"key":"707_CR12","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","volume":"23","author":"TE Witzig","year":"2005","unstructured":"Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol. 2005;23:5347\u201356.","journal-title":"J Clin Oncol"},{"key":"707_CR13","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","volume":"27","author":"G Hess","year":"2009","unstructured":"Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator\u2019s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009;27:3822\u20139.","journal-title":"J Clin Oncol"},{"issue":"Suppl. 2","key":"707_CR14","first-page":"436","volume":"94","author":"T Witzig","year":"2009","unstructured":"Witzig T, Habermann T, Reeder C, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed non-Hodgkin lymphoma and Hodgkin disease (HD). Haematologica. 2009;94(Suppl. 2):436. Abstract 1081.","journal-title":"Haematologica"},{"key":"707_CR15","doi-asserted-by":"crossref","unstructured":"Johnston PB, Ansell SM, Colgan JP, et al. Phase II trial of the oral mTOR inhibitor everolimus (RAD001) for patients with relapsed or refractory lymphoma. J Clin Oncol. 2007; 25 18S June 20 Suppl:8055 (abstract).","DOI":"10.1200\/jco.2007.25.18_suppl.8055"},{"key":"707_CR16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/jjco\/hyp120","volume":"40","author":"I Okamoto","year":"2010","unstructured":"Okamoto I, Doi T, Ohtsu A, et al. Phase I clinical and pharmacokinetic study of RAD001 (everolimus) administered daily to Japanese patients with advanced solid tumors. Jpn J Clin Oncol. 2010;40:17\u201323.","journal-title":"Jpn J Clin Oncol"},{"key":"707_CR17","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1002\/sim.3230","volume":"27","author":"B Neuenschwander","year":"2008","unstructured":"Neuenschwander B, Branson M, Gsponer T. Critical aspects of the Bayesian approach to phase I cancer trials. Stat Med. 2008;27:2420\u201339.","journal-title":"Stat Med"},{"key":"707_CR18","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1200\/JCO.2007.14.0988","volume":"26","author":"A O\u2019Donnell","year":"2008","unstructured":"O\u2019Donnell A, Faivre S, Burris HA III, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol. 2008;26:1588\u201395.","journal-title":"J Clin Oncol"},{"key":"707_CR19","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. J Clin Oncol. 1999;17:1244\u201353.","journal-title":"J Clin Oncol"},{"key":"707_CR20","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1200\/JCO.2007.14.5482","volume":"26","author":"J Tabernero","year":"2008","unstructured":"Tabernero J, Rojo F, Calvo E, et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol. 2008;26:1603\u201310.","journal-title":"J Clin Oncol"},{"key":"707_CR21","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1158\/1078-0432.CCR-06-0764","volume":"12","author":"KWL Yee","year":"2006","unstructured":"Yee KWL, Zeng Z, Konopleva M, et al. Phase I\/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2006;12:5165\u201373.","journal-title":"Clin Cancer Res"},{"key":"707_CR22","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1158\/1078-0432.CCR-07-1372","volume":"14","author":"DA Rizzieri","year":"2008","unstructured":"Rizzieri DA, Feldman E, DiPersio JF, et al. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2008;14:2756\u201362.","journal-title":"Clin Cancer Res"},{"key":"707_CR23","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/j.ejca.2006.03.015","volume":"42","author":"I Duran","year":"2006","unstructured":"Duran I, Siu LL, Oza AM, et al. Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer. 2006;42:1875\u201380.","journal-title":"Eur J Cancer"},{"key":"707_CR24","doi-asserted-by":"crossref","unstructured":"Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer. 2010 Jun 14 [Epub ahead of print].","DOI":"10.1002\/cncr.25219"},{"key":"707_CR25","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/ajh.21664","volume":"85","author":"PB Johnston","year":"2010","unstructured":"Johnston PB, Inwards DJ, Colgan JP, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol. 2010;85:320\u20134.","journal-title":"Am J Hematol"},{"key":"707_CR26","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1200\/JCO.2009.24.0994","volume":"28","author":"IM Ghobrial","year":"2010","unstructured":"Ghobrial IM, Gertz M, Laplant B, et al. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstr\u00f6m macroglobulinemia. J Clin Oncol. 2010;28:1408\u201314.","journal-title":"J Clin Oncol"},{"key":"707_CR27","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1002\/cncr.25005","volume":"116","author":"CS Zent","year":"2010","unstructured":"Zent CS, LaPlant BR, Johnston PB, et al. The treatment of recurrent\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation. Cancer. 2010;116:2201\u20137.","journal-title":"Cancer"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-010-0707-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-010-0707-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-010-0707-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,31]],"date-time":"2024-03-31T17:16:24Z","timestamp":1711905384000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-010-0707-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,23]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["707"],"URL":"https:\/\/doi.org\/10.1007\/s12185-010-0707-5","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,23]]}}}